Biocompatibles adds technology platform and two licences
This article was originally published in Clinica
Executive Summary
Biocompatibles, a darling of the UK stock market since its entry into the stent market late last year, has added a new technology platform and two new licences to its own coatings know-how based on phosphorylcholine (PC). Together with its 1996 results, it also reported that it launched its DivYsio stent in selected markets in February. The company's shares doubled since its share issue last November, closing at £10.90 on March 26th.